SEC Comment Letter 0000000000-24-014278 to CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738) (CASIF)
CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)
Date: Dec. 26, 2024 · CIK: 0001962738 · Accession: 0000000000-24-014278
AI Filing Summary & Sentiment
File numbers found in text: 333-283998
Letter
December 26, 2024 Rui Zhang VP of Finance and Operations CASI Pharmaceuticals, Inc. 9620 Medical Center Drive, Suite 300 Rockville, MD 20850 Re:CASI Pharmaceuticals, Inc. Registration Statement on Form F-3 Filed December 20, 2024 File No. 333-283998 Dear Rui Zhang: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:C. Christopher Murillo, Esq.
Show Raw Text
December 26, 2024
Rui Zhang
VP of Finance and Operations
CASI Pharmaceuticals, Inc.
9620 Medical Center Drive, Suite 300
Rockville, MD 20850
Re:CASI Pharmaceuticals, Inc.
Registration Statement on Form F-3
Filed December 20, 2024
File No. 333-283998
Dear Rui Zhang:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:C. Christopher Murillo, Esq.